Galmed Pharmaceuticals Granted Nasdaq Extension

Galmed Pharmaceuticals (GLMD) has released an update.

Galmed Pharmaceuticals Ltd. has been granted an additional 180-day period by Nasdaq to meet the minimum bid price requirement after failing to comply within the initial timeframe. The company’s shares must reach a bid price of at least $1.00 for 10 consecutive business days before September 16, 2024, to avoid delisting. An appeal process is available if the company does not meet the compliance deadline.

For further insights into GLMD stock, check out TipRanks’ Stock Analysis page.